Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a personalized anti-tumor immune response to benefit cancer patients in need   Lund, Sweden, 17 April 2026 – Asgard Therapeutics, a privately held biotech company pioneering […]